← Back to all signals
RESEARCH PAPER ANALYSIS

Prognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).

AI interpretation is pending for this paper.

Open original publication →
PMID39726711
JournalFrontiers in oncology
Publication Date2024-12-12
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Orbital rhabdomyosarcoma (RMS) is often limited to the orbital cavity and has a favorable prognosis. In some cases, the tumor can erode the orbital bone and behave as a parameningeal RMS (PM-RMS); thus, it is treated more intensively. However, the current protocols do not provide any guidance on how to consider different grades of bone erosion (BE) that can vary widely, hampering a uniform classification and the subsequent treatment assignment. With the aim of clarifying the role of BE as a risk factor, we analyzed patients with orbital RMS included in the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol. METHODS: We retrospectively analyzed the radiological reports of 199 patients with orbital RMS (PM or not) and defined three grades of BE: minimal (thinning of the bone), moderate (focal bone lysis), and extensive (complete cortical destruction). RESULTS: BE was present in 55 of the 199 (27.6%) patients, which was classified as minimal in 27, moderate in 7, and extensive in 21. Tumors with extensive BE were more frequently large (>5 cm, p = 0.0008) and invasive (T2, p = 0.001). With a median follow-up of 70.4 months (range = 7.1-167.7), a total of 183 patients are alive, with 5-year event-free survival (EFS) and overall survival (OS) rates of 76% (95%CI = 69.2-81.3) and 92% (95%CI = 86.7-94.8), respectively. Patients without any BE had better OS (95% vs. 81%, p = 0.001), but not EFS. Patients with no/minimal/moderate BE had better EFS and OS compared with patients with extensive BE [EFS of 78.1 (95%CI = 71.1-83.5) vs. 57.1 (95%CI = 33.8-74.9), p = 0.0114, respectively, and OS of 94.0 (95%CI = 89.2-96.8) vs. 71.1 (95%CI = 46.6-85.9), p < 0.0001, respectively]. Events and metastatic relapses (in all cases CNS/meningeal) were more frequent in patients with extensive BE. CONCLUSIONS: Only those patients with orbital RMS and extensive BE should be considered as PM and should be treated accordingly.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Effects of nutritional intervention on insulin resistance-associated inflammatory biomarkers and gene polymorphisms in gestational diabetes mellitus. Journal of medical biochemistry 67.45 2 Factors influencing health-related quality of life in children with leukemia in Saudi Arabia: a cross- sectional study. BMC pediatrics 63.8 3 Breast Cancer Patients' Parenting Concerns User Personas: A Qualitative Analysis. Current oncology (Toronto, Ont.) 57.4 4 Molecular Pathogenesis, Tumor Microenvironment and Health Disparities in Select Pediatric Solid Tumors: An Integrative Narrative Review. Diseases (Basel, Switzerland) 65.5 5 Expression VIII: Final Results of the Individual Perception and Level of Information of Patients with Borderline Tumors of the Ovary. Current oncology (Toronto, Ont.) 67.8 6 Adolescents and young adults with cancer in Switzerland: a large retrospective single-centre cohort analysis of key care pathways and outcomes by sex and age. Swiss medical weekly 79.6 7 Cellular and Immunotherapy for Pediatric Brain Tumors: A Primer. Current oncology (Toronto, Ont.) 62.52 8 Exercise and Childhood Cancer: From Science to Life "The 3rd Pediatric Exercise Oncology Congress Meets FORTEe". Current oncology (Toronto, Ont.) 66.9 9 Mitochondrial Genomic Alterations in Pediatric Acute Lymphoblastic Leukemia: Implications for Methotrexate-Induced Neurotoxicity and Ethnic Disparities. Cancer medicine 58.62 10 Two-Decade Trends in Radiotherapy Patterns and Clinical Outcomes for Soft Tissue Sarcoma: A Nationwide Study in South Korea (2005-2023). Cancer medicine 72.64 11 Re-resection at first recurrence is associated with prolonged survival in young patients with high-grade glioma: A multi-center study. Neuro-oncology advances 71.92 12 Risk Modulation by Electronic Cigarette Consumption in Cardiovascular Disease and Its Relevance in Cardiac Surgery-A Narrative Review. Journal of cardiovascular development and disease 55.0 13 Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review. Frontiers in endocrinology 86.1 14 Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment. Frontiers in pharmacology 82.8 15 A PDGFRB-CD44-MIF crosstalk promotes cancer-associated cellular phenotypes in ATRT-TYR/MYC cell lines. Frontiers in oncology 51.6 16 Case Report: Two cases of secondary malignant neoplasms following treatment in pediatric patients. Frontiers in pediatrics 61.14 17 Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder. Frontiers in molecular neuroscience 62.9 18 Clinical Outcomes and New Treatments in Pediatric Brain Tumors. Current oncology (Toronto, Ont.) 52.74 19 Quality of Life in Ukrainian Children and Adolescents with Cancer Relocated to Switzerland During the Russian-Ukrainian War: An Exploratory Multicenter Study. Current oncology (Toronto, Ont.) 59.9 20 Vitamin D and Gastric Cancer: A Systematic Review and Meta-Analysis. Medical sciences (Basel, Switzerland) 73.0 21 "If I want to tap into a cord blood bank later, I felt that I should do my part and donate": Mutualism in women's accounts of umbilical cord blood donation. Social science & medicine (1982) 56.0 22 Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering. Research square 58.8 23 Oncohistone inhibition reshapes tumor-microenvironment communication in Diffuse Midline Glioma (DMG). bioRxiv : the preprint server for biology 58.8 24 Prenatally Detected Neonatal Neuroblastoma Associated with Achondroplasia and an SDHA Variant. Neurology international 62.8 25 Preclinical evaluation of ixazomib for high-risk pediatric brain tumors. bioRxiv : the preprint server for biology 59.7 26 Fusion Oncoprotein EWSR1::FLI1 Invades Nucleosomes at Consensus ETS Motifs and GGAA Microsatellites. bioRxiv : the preprint server for biology 56.0 27 Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing. Medical sciences (Basel, Switzerland) 65.9 28 Management of intractable emergence agitation with emotional and behavioural disinhibition in a child with anxiety requiring multiple anaesthetics. Anaesthesia reports 60.0 29 [Spitz tumors]. Pathologie (Heidelberg, Germany) 56.0 30 Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. Pituitary 61.4 31 Successful Cytotoxic Chemotherapy-Free Bridging to Hematopoietic Stem Cell Transplantation With Dasatinib and Prednisolone/Blinatumomab for Relapsed Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Pediatric blood & cancer 55.06 32 Physical activity and exercise in pediatric oncology: conceptual distinctions and clinical implications. Turkish journal of physical medicine and rehabilitation 62.0
PATIENT-FRIENDLY SUMMARY

Prognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic